15
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Flaviviruses have an increasing global impact as arthropod-transmitted human pathogens, exemplified by Zika, dengue, yellow fever (YF), West Nile, Japanese encephalitis, and tick-borne encephalitis (TBE) viruses. Since all flaviviruses are antigenically related, they are prone to phenomena of immunological memory (‘original antigenic sin’), which can modulate immune responses in the course of sequential infections and/or vaccinations. In our study, we analyzed the influence of pre-existing YF vaccine-derived immunity on the antibody response to TBE vaccination. By comparing samples from YF pre-vaccinated and flavivirus–naive individuals, we show that YF immunity not only caused a significant impairment of the neutralizing antibody response to TBE vaccination but also a reduction of the specific TBE virus neutralizing activities (NT/ELISA-titer ratios). Our results point to a possible negative effect of pre-existing cross-reactive immunity on the outcome of flavivirus vaccination that may also pertain to other combinations of sequential flavivirus infections and/or vaccinations.

          Flavivirus vaccines: Yellow Fever vaccine commits ‘original antigenic sin’

          Flaviviruses, such as Yellow Fever (YF) virus and Tick-borne encephalitis (TBE) virus, share a certain level of antigenic relatedness, meaning that pre-existing immunity to one flavivirus species can impact the antibody response to a second — a phenomenon known as ‘original antigenic sin’. A team led by Franz X. Heinz at the Medical University of Vienna investigate the impact of pre-vaccination with the YF vaccine (a minimum of one year earlier) on subsequent vaccination against TBE. Overall, YF pre-immunity significantly reduced generation of TBE neutralizing antibodies compared to flavivirus-naive individuals, but there was a striking level of inter-individual variation. Although even the YF-vaccinated individuals produced sufficient TBE neutralizing titers to be considered potentially protective, these findings suggest that the influence of ‘original antigenic sin’ might need to be taken into account for flavivirus vaccination protocols.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Epidemic arboviral diseases: priorities for research and public health.

          For decades, arboviral diseases were considered to be only minor contributors to global mortality and disability. As a result, low priority was given to arbovirus research investment and related public health infrastructure. The past five decades, however, have seen an unprecedented emergence of epidemic arboviral diseases (notably dengue, chikungunya, yellow fever, and Zika virus disease) resulting from the triad of the modern world: urbanisation, globalisation, and international mobility. The public health emergency of Zika virus, and the threat of global spread of yellow fever, combined with the resurgence of dengue and chikungunya, constitute a wake-up call for governments, academia, funders, and WHO to strengthen programmes and enhance research in aedes-transmitted diseases. The common features of these diseases should stimulate similar research themes for diagnostics, vaccines, biological targets and immune responses, environmental determinants, and vector control measures. Combining interventions known to be effective against multiple arboviral diseases will offer the most cost-effective and sustainable strategy for disease reduction. New global alliances are needed to enable the combination of efforts and resources for more effective and timely solutions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.

            Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million infections occurring annually. To gain insight into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and fully neutralized virus produced in either insect cells or primary human cells, with 50% neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses.

                Bookmark

                Author and article information

                Contributors
                karin.stiasny@meduniwien.ac.at
                franz.x.heinz@meduniwien.ac.at
                Journal
                NPJ Vaccines
                NPJ Vaccines
                NPJ Vaccines
                Nature Publishing Group UK (London )
                2059-0105
                6 September 2019
                6 September 2019
                2019
                : 4
                : 38
                Affiliations
                [1 ]ISNI 0000 0000 9259 8492, GRID grid.22937.3d, Center for Virology, , Medical University of Vienna, ; Vienna, Austria
                [2 ]ISNI 0000 0004 0478 9977, GRID grid.412004.3, Division of Infectious Diseases, Department of Medicine, , University Hospital of Zurich, ; Zurich, Switzerland
                [3 ]ISNI 0000 0000 8517 9062, GRID grid.411339.d, Present Address: Department of Medicine, , University Hospital of Leipzig, ; Leipzig, Germany
                [4 ]ISNI 0000000405446183, GRID grid.486422.e, Present Address: Boehringer Ingelheim RCV GmbH & Co KG, ; Vienna, Austria
                [5 ]Present Address: Hookipa Pharma, Vienna, Austria
                [6 ]ISNI 0000 0001 1515 9979, GRID grid.419481.1, Present Address: Novartis, ; Rotkreuz, Switzerland
                [7 ]ISNI 0000 0001 0697 1703, GRID grid.452288.1, Present Address: Department of Medicine, , Cantonal Hospital of Winterthur, ; Winterthur, Switzerland
                Author information
                http://orcid.org/0000-0001-9755-2060
                http://orcid.org/0000-0002-0222-9832
                http://orcid.org/0000-0002-1902-8674
                http://orcid.org/0000-0002-7191-4331
                Article
                133
                10.1038/s41541-019-0133-5
                6731309
                31508246
                24b9e750-86bd-4999-9464-3c6ade4aa361
                © The Author(s) 2019

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 14 June 2019
                : 19 August 2019
                Categories
                Article
                Custom metadata
                © The Author(s) 2019

                viral infection,virology
                viral infection, virology

                Comments

                Comment on this article